{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:07:57Z","timestamp":1791299277813,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Joint Project Manager Medical Countermeasure Systems (JPM-MCS)","award":["B.09"],"award-info":[{"award-number":["B.09"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.antiviral.2017.12.021","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T02:47:52Z","timestamp":1514429272000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus"],"prefix":"10.1016","volume":"151","author":[{"given":"Sandra L.","family":"Bixler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Bocan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S.","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Van Tongeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-6192","authenticated-orcid":false,"given":"Lisa H.","family":"Cazares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Nuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Soloveva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Koistinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Giesing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-353X","authenticated-orcid":false,"given":"Robert","family":"Lenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Bavari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis K.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.antiviral.2017.12.021_bib1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2017.12.021_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1242\/dmm.000471","article-title":"Disease modeling for Ebola and Marburg viruses","volume":"2","author":"Bente","year":"2009","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.antiviral.2017.12.021_bib3","article-title":"Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with ebola virus","author":"Bixler","year":"2017","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.antiviral.2017.12.021_bib4","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.antiviral.2017.12.021_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3201\/eid0805.010284","article-title":"Evaluation in nonhuman primates of vaccines against Ebola virus","volume":"8","author":"Geisbert","year":"2002","journal-title":"Emerg. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2017.12.021_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.antiviral.2009.02.201","article-title":"Effect of T-705 treatment on western equine encephalitis in a mouse model","volume":"82","author":"Julander","year":"2009","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2017.12.021_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2017.12.021_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses","volume":"61","author":"Madelain","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2017.12.021_bib9","unstructured":"Marburg virus disease - Uganda. http:\/\/www.who.int\/csr\/don\/25-october-2017-marburg-uganda\/en\/."},{"issue":"2","key":"10.1016\/j.antiviral.2017.12.021_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","article-title":"Dose regimen of favipiravir for Ebola virus disease","volume":"15","author":"Mentre","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/j.antiviral.2017.12.021_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S2213-2600(15)00180-0","article-title":"Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain","volume":"3","author":"Mora-Rillo","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.antiviral.2017.12.021_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.antiviral.2008.07.009","article-title":"Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents","volume":"80","author":"Morrey","year":"2008","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.antiviral.2017.12.021_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"5","key":"10.1016\/j.antiviral.2017.12.021_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"Oestereich","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2017.12.021_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2017.12.021_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect Guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.antiviral.2017.12.021_bib17","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1473-3099(15)00229-7","article-title":"Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report","volume":"15","author":"Schibler","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/j.antiviral.2017.12.021_bib18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1517\/17460441.2015.1035252","article-title":"Animal models for ebolavirus countermeasures discovery: what defines a useful model?","volume":"10","author":"Shurtleff","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"issue":"3","key":"10.1016\/j.antiviral.2017.12.021_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"issue":"11","key":"10.1016\/j.antiviral.2017.12.021_bib20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2217\/fvl.13.98","article-title":"Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice","volume":"8","author":"Smee","year":"2013","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2017.12.021_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.antiviral.2017.12.021_bib22","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.3390\/v6114666","article-title":"Euthanasia assessment in ebola virus infected nonhuman primates","volume":"6","author":"Warren","year":"2014","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.antiviral.2017.12.021_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004456","article-title":"Delayed time-to-treatment of an antisense Morpholino Oligomer is effective against lethal Marburg virus infection in cynomolgus macaques","volume":"10","author":"Warren","year":"2016","journal-title":"PLoS Negl. Trop. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T21:54:07Z","timestamp":1535147647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217307374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":23,"alternative-id":["S0166354217307374"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.021","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}